Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00846846 · ClinicalTrials.gov registry record · Phase 4
PROTECT Continued Access Post Marketing Surveillance Trial
A Phase 4 study, sponsored by Medtronic Vascular.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,018
- Enrollment target
NCT00846846 is a Phase 4 study that has completed, run by Medtronic Vascular. The registered enrollment target is 1,018 participants.
The verdict
NCT00846846, a Phase 4 study, has completed, sponsored by Medtronic Vascular.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,018 participants
- Enrollment target
Study Summary
In order to expand safety information in patients treated with the Endeavor Drug Eluting Stent System, or next generation model, a Continued Access (CA) study is added to the PROTECT Trial. The amended study is "PROTECT CONTINUED ACCESS" ("PROTECT CA").
Interventions
- DEVICE Endeavor® Zotarolimus Eluting Coronary Stent System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,018 participants |
| Start Date | 2009-01 |
| Est. Completion | 2015-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00846846
The ClinicalTrials.gov registry entry for NCT00846846 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,018 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Vascular, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Endeavor® Zotarolimus Eluting Coronary Stent System is the first listed.
NCT00846846 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00846846 about?
NCT00846846 is a clinical study titled "PROTECT Continued Access Post Marketing Surveillance Trial". In order to expand safety information in patients treated with the Endeavor Drug Eluting Stent System, or next generation model, a Continued Access (CA) study is added to the PROTECT Trial. The amended study is "PROTECT CONTINUED ACCESS" ("PROTECT CA").
What is the current status of trial NCT00846846?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,018 participants. The study started on 2009-01. Estimated completion is 2015-03.
What interventions are being tested in trial NCT00846846?
The interventions under investigation include: Endeavor® Zotarolimus Eluting Coronary Stent System (DEVICE).
Who is sponsoring clinical trial NCT00846846?
This trial is sponsored by Medtronic Vascular, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.